Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Jan 2014

Mandrekar Sumithra J

Abstract excerpt

The primary goal of phase I dose-finding trials has been historically to understand the safety profile of a new treatment/regimen and establish the maximum tolerated dose (MTD) for further investigation in a specific tumor type. These designs hinged on the assumption that the highest safe dose is also likely to be the most efficacious dose. In the current era of stratified medicine and targeted therapies, these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endpoint Determination

Share to Maximum Tolerated Dose

Share to Molecular Targeted Therapy

Share to Patient Selection

Share to Research Design

Share to Transcriptome

Source

Identifiers

PMID: 24857087
DOI: 10.14694/EdBook_AM.2014.34.e107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.PMID 24857087Read ↗

Application of genotype-guided cancer therapy in solid tumors.Semantic proximity Read ↗

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label updateSemantic proximity Read ↗

Phenotype versus genotype to optimize cancer dosing in the clinical setting-focus on 5-fluorouracil and tyrosine kinase inhibitors.Semantic proximity Read ↗

Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement.Semantic proximity Read ↗

Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.Semantic proximity Read ↗

Evolving or Immutable - Phase I Solid Tumor Trials in the Era of Precision OncologySemantic proximity Read ↗

Clinical trial designs for prospective validation of biomarkers.Semantic proximity Read ↗

Sequential designs for individualized dosing in phase I cancer clinical trials.Semantic proximity Read ↗

Nontoxicity Endpoints in Phase I Trial Designs for Targeted, Non-Cytotoxic AgentsSemantic proximity Read ↗

On the efficiency of targeted clinical trials.Semantic proximity Read ↗

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisSemantic proximity Read ↗

A dose-finding approach for genomic patterns in phase I trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.